Core Insights - Cellgenic, a subsidiary of Regenerative Medical Technologies Group (RMTG), has commenced full-scale manufacturing at its biologics facility in Cancún, Mexico, producing six product lines for international markets [2][3]. Manufacturing Operations - The Cancún facility is the first in the region specifically designed for external manufacturing and international distribution of biologics, actively shipping products to authorized medical professionals across compliant markets [3]. - The facility's operational launch follows a soft opening during the ISSCA Global Regenerative Medicine Summit in September 2025, which saw participation from physicians and scientists from over 30 countries [3]. Financial Performance - The full-scale launch is expected to add a significant revenue stream to RMTG's integrated business model, building on recent financial momentum with Q1 2025 sales of $1.35 million, reflecting a 67% year-over-year growth, and operational profits of $134,000 [4]. Product Lines - The Cancún facility is producing and distributing the following biologic products: - Exosome Flow Series - Lyophilized Exosomes - Umbilical Cord-Derived Mesenchymal Stem Cells (MSCs) - Natural Killer (NK) Cells - Allogeneic Fibroblasts - Sterile Diluents [6]. Manufacturing Standards - All biologics are produced under xeno-free conditions, ensuring no animal-derived components are used, which aligns with evolving regulatory expectations and supports broader international acceptance [7]. Integrated Model - The facility operates in coordination with the Cellular Hope Institute and ISSCA, providing educational opportunities for physicians and researchers, enhancing transparency and professional dialogue in regenerative medicine [8][9]. Future Growth Initiatives - Cellgenic has outlined a 2026 pipeline that includes: - Exosome-peptide combination formulations - Multi-peptide blended delivery formats - Cell-free conditioned media (secretome) - Cryopreserved cell banking services - Private-label and white-label manufacturing programs - An Authorized Distributor Program to support long-term collaboration and international growth [9][10]. Company Overview - RMTG, through its Global Stem Cells Group subsidiary, operates in over 30 countries, focusing on regenerative medicine solutions and physician education via its ISSCA platform [11][12].